Palivizumab is a Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody. The mechanism of action of palivizumab is as a Fusion Protein Inhibitor. It is grouped under the following drug class(es): Monoclonal antibodies. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Immunoglobulin G1 and palivizumabum. Its PubChem CID is 481101776.
Palivizumab
| CAS No | 188039-54-5 |
|---|---|
| Molecular Formula | C6470H10056N1700O2008S50 |
| Molecular Weight | 148,000 Daltons |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Palivizumab is a Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody. The mechanism of action of palivizumab is as a Fusion Protein Inhibitor. It is grouped under the following drug class(es): Monoclonal antibodies.
The listed CAS number is 188039-54-5.
The listed molecular formula is C6470H10056N1700O2008S50.
The listed molecular weight is 148,000 Daltons.
The source lists Immunoglobulin G1 and palivizumabum.
It is listed under Monoclonal antibodies.